Falciparum Malaria Clinical Trial
Official title:
Exposure of Human Volunteers to Live Malaria Sporozoites Under Chloroquine Prophylaxis
The objective of the study is to induce a protective immune response against malaria in healthy human volunteers. The different parts of the immune response will then be studied.
Efforts to develop vaccines against malaria still represent a substantial focus of current
research activities. Factors that have hampered the development of a subunit vaccine include
the complexity of the malaria life cycle, the wide variety of immune response induced by the
malaria parasite, and an incomplete knowledge of protective immunity. This study is
therefore aimed at inducing protective immunity against malaria in 15 healthy volunteers.
Volunteers will be exposed to the bites of infectious mosquitoes 3 times with live P.
falciparum sporozoites under chloroquine prophylaxis. Challenge with infected mosquitoes
will be given after stopping chloroquine prophylaxis.
Five volunteers will form a control group; they will be exposed to non-infectious mosquitoes
under chloroquine prophylaxis.
Endpoints include the time and height of parasitemia after challenge, the development of
fever and immunological parameters.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00440752 -
The Impact of Artemether-Lumefantrine on Genes Associated With Antimalarial Resistance
|
N/A | |
| Completed |
NCT01144702 -
Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Malaria by Plasmodium Falciparum
|
Phase 2/Phase 3 | |
| Terminated |
NCT00400101 -
Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Peptides
|
Phase 1 | |
| Completed |
NCT01350856 -
Tracking Resistance to Artemisinin (TRAC)
|
Phase 4 | |
| Completed |
NCT00859807 -
A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects
|
Phase 4 | |
| Completed |
NCT04222088 -
TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014
|
||
| Completed |
NCT01115439 -
Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria
|
N/A | |
| Completed |
NCT00282919 -
A Three Day Trial of Azithromycin Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria
|
Phase 2 | |
| Completed |
NCT04422015 -
Biological Mechanisms in Afebrile P. Falciparum Malaria
|
||
| Completed |
NCT00894374 -
Bioequivalence Study Comparing Artesunate Tablet To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects
|
Phase 1 | |
| Completed |
NCT00894660 -
A Bioequivalence Study Comparing Amodiaquine Tablet (Pfizer) To Amodiaquine Tablets (Arsuamoon-Guilin China) In Healthy Subjects
|
Phase 1 | |
| Completed |
NCT00493363 -
Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia
|
N/A | |
| Completed |
NCT00158548 -
ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan
|
Phase 3 | |
| Withdrawn |
NCT04289558 -
Nitrite Infusion in Children With Malaria
|
Phase 1 | |
| Completed |
NCT01374126 -
Azithromycin Combination Therapy for the Treatment of Severe Malaria
|
Phase 2 | |
| Completed |
NCT00722150 -
Artemisinin Resistance in Cambodia II
|
N/A | |
| Completed |
NCT00157833 -
A Randomized Trial of Coartemether and Artekin for the Treatment of Uncomplicated Malaria in Papua, Indonesia.
|
N/A | |
| Completed |
NCT00513669 -
Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania
|
Phase 1 | |
| Completed |
NCT00403260 -
Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients
|
Phase 3 | |
| Completed |
NCT01365598 -
Evaluation of the Gametocytocidal Efficacy and Safety of Primaquine in Uncomplicated Falciparum Malaria in Uganda
|
Phase 3 |